NEC Bio
NEC Bio is a Netherlands-based biotechnology company that leads 2 cancer trials in OnCo, testing the personalised neoantigen vaccine NECVAX-NEO1 in triple-negative breast cancer and advanced solid tumours.
Overview
NEC Bio is the holding company set up by NEC Corporation in 2023 to unify its AI-driven drug discovery and development activities; it manages NEC OncoImmunity in Oslo and NEC Bio Therapeutics in Mannheim. The group applies its immune-recognition AI platform to personalised neoantigen cancer vaccines, including NECVAX-NEO1. It is a wholly owned subsidiary of NEC Corporation. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06631079 (phase 1/2, Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy...) and NCT06631092 (phase 1/2, Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-nega...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.